1215357-89-3

Upstream product

• 123-75-1 pyrrolidine 
• 371171-21-0 2,4-dichloro-6-(3,4-dimethoxy)phenylpyrimidine 
• 725272-75-3 3,4-dimethoxyphenylborate 

Downstream Products

• 1215357-90-6 4-(3,4-dimethoxyphenyl)-6-(pyrrolidin-1-yl)-2-[(E)-2-(tributylstannyl)ethenyl]pyrimidine 
• 1415982-96-5 2-{(E)-2-[4-(1-imidazolyl)-quinazolin-2-yl]}ethenyl-4-(3,4-dimethoxy)phenyl-6-(pyrrolidin-1-yl)pyrimidine 

Relevant academic research and scientific papers

Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor

The present invention relates to a therapeutic or prophylactic method for treating Parkinson's disease by administering an effective amount of a compound having a phosphodiesterase 10 inhibitory activity; and also relates to a pharmaceutical composition for treatment or prophylaxis of Parkinson's disease comprising as an active ingredient a compound having a phosphodiesterase 10 inhibitory activity. Moreover, the present invention relates to a method for enhancing dopamine signal in the brain, which comprises administering an effective amount of a compound having a phosphodiesterase 10 inhibitory activity; and also relates to pharmaceutical composition for enhancing dopamine signal in brain comprising as an active ingredient a compound having a phosphodiesterase 10 inhibitory activity.